Industry
Biotechnology
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Loading...
Open
303.29
Mkt cap
6.3B
Volume
934K
High
303.29
P/E Ratio
-11.53
52-wk high
368.29
Low
272.72
Div yield
N/A
52-wk low
166.00
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 12:32 pm
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 12:27 pm
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 11:55 am
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 10:23 am
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 9:33 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 8:53 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 8:40 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.